Clinical Celltrion gets Canadian priority review for Covid-19 antibody treatment,...

Celltrion gets Canadian priority review for Covid-19 antibody treatment, Regdanvimab


Canadian biopharmaceutical company, Celltrion Healthcare Canada Ltd., has been granted priority review by Health Canada for its new COVID-19 treatment, Regdanvimab  ̶  a monoclonal antibody.

The company, in May, had filed a new drug submission (NDS) to the agency. The screening phase of the drug has been completed and application has been approved for rolling review, according to the company.

The rolling submission has allowed the company to submit safety and efficacy data in a continuous manner as soon as it becomes available, accelerating the overall reviewing process by the agency.   

Jovan Antunovic, Celltrion Healthcare Canada commercial director, stated, “We are pleased the new drug submission has been screened and accepted for review by Health Canada and anticipate this accelerated review process will enable people in Canada to have access to safe and effective treatment against Covid-19 as early as possible.”

He further added, “The initiation of a rolling submission for Regdanvimab (CT-P59) in Canada is a significant milestone and we remain committed to closely working with the Canadian regulatory authorities.”

The data obtained from the pre-clinical trials has indicated that the antibody has the potential to neutralize the SARS-CoV-2 virus by attaching to its receptor-binding domain (RBD).

Global phase III trials of the drug have mitigated the risks of hospitalization, oxygen treatment and death due to COVID-19, by 72%, in patients having high vulnerability to the disease.

On the whole, for all treated patients, 70% risk has been reduced through the drug in contrast to the placebo.

Besides, the drug has offered a minimum of 4.7 days decrease in clinical recovery time in patients with higher risks of disease progression; and for overall patient population, it has offered a 4.9 days decrease, comparing with placebo.

By March, Regdanvimab managed to get recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), to be used as a treatment for patients with high progression risks of COVID-19.

Currently, Celltrion is working on developing an antibody cocktail with Regdanvimab, to neutralize several emergent variants of SARS-CoV-2.

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you